世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界のドラベ症候群治療市場 2018-2022年

Global Dravet Syndrome Treatment Market 2018-2022

IRTNTR23737

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年9月US$2,500
シングルユーザライセンス
104

サマリー

この調査レポートは世界のドラベ症候群治療市場を分析・予測したTechNavioの市場調査報告書です。

Description

About Dravet Syndrome
Dravet syndrome is a rare disease and is a severe form of epilepsy that is a part of the group of diseases known as SCN1A-related seizure disorders. It occurs due to a mutation in the SCN1A gene, which is required for the proper function of brain cells.
Technavio’s analysts forecast the Global Dravet Syndrome Treatment Market to grow at a CAGR of 8.35% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the dravet syndrome treatment market. To calculate the market size, the report considers the revenue generated by the sale of drugs for the treatment of dravet syndrome across the globe.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, dravet syndrome treatment market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Biocodex
- Epygenix Therapeutics
- GW Pharmaceuticals
- OPKO Health
- Zogenix
Market driver
- Rising number of strategic alliances
- For a full, detailed list, view our report

Market challenge
- Low awareness
- For a full, detailed list, view our report

Market trend
- Increased use of new generation drugs
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2022 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: PIPELINE LANDSCAPE
- Drugs under development
PART 08: MARKET SEGMENTATION BY PRODUCT
- Segmentation by product
- Comparison by product
- SGD - Market size and forecast 2017-2022
- TGD - Market size and forecast 2017-2022
- FGD - Market size and forecast 2017-2022
- Market opportunity by product
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas - Market size and forecast 2017-2022
- EMEA - Market size and forecast 2017-2022
- APAC - Market size and forecast 2017-2022
Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 13: MARKET TRENDS
- Increased use of new generation drugs
- Advances in biomedical sciences
- Strong pipeline
PART 14: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 15: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Biocodex
- Epygenix Therapeutics
- GW Pharmaceuticals
- OPKO Health
- Zogenix
PART 16: APPENDIX
- List of abbreviations
-
-
Exhibit 01: Parent market
Exhibit 02: Global CNS disorders drugs market segmentation
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global Dravet syndrome treatment market - Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global Dravet syndrome treatment market - Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Molecules in the pipeline
Exhibit 20: Global Dravet syndrome treatment market by product - Market share 2017-2022 (%)
Exhibit 21: Comparison by product
Exhibit 22: SGD - Market size and forecast 2017-2022 ($ mn)
Exhibit 23: SGD - Year-over-year growth 2018-2022 (%)
Exhibit 24: TGD - Market size and forecast 2017-2022 ($ mn)
Exhibit 25: TGD - Year-over-year growth 2018-2022 (%)
Exhibit 26: FGD - Market size and forecast 2017-2022 ($ mn)
Exhibit 27: FGD - Year-over-year growth 2018-2022 (%)
Exhibit 28: Market opportunity by product
Exhibit 29: Customer landscape
Exhibit 30: Global Dravet syndrome treatment market - Market share by geography 2017-2022 (%)
Exhibit 31: Regional comparison
Exhibit 32: Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 33: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 34: Top 3 countries in Americas
Exhibit 35: EMEA - Market size and forecast 2017-2022 ($ mn)
Exhibit 36: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 37: Top 3 countries in EMEA
Exhibit 38: APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 39: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 40: Top 3 countries in APAC
Exhibit 41: Market opportunity
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: Biocodex - Overview
Exhibit 48: Biocodex - Organizational developments
Exhibit 49: Biocodex - Key offerings
Exhibit 50: Biocodex - Key customers
Exhibit 51: Epygenix Therapeutics - Overview
Exhibit 52: Epygenix Therapeutics - Organizational developments
Exhibit 53: Epygenix Therapeutics - Key offerings
Exhibit 54: Epygenix Therapeutics - Key customers
Exhibit 55: GW Pharmaceuticals - Overview
Exhibit 56: GW Pharmaceuticals - Business segments
Exhibit 57: GW Pharmaceuticals - Organizational developments
Exhibit 58: GW Pharmaceuticals - Geographic focus
Exhibit 59: GW Pharmaceuticals - Segment focus
Exhibit 60: GW Pharmaceuticals - Key offerings
Exhibit 61: GW Pharmaceuticals - Key customers
Exhibit 62: OPKO Health - Overview
Exhibit 63: OPKO Health - Business segments
Exhibit 64: OPKO Health - Organizational developments
Exhibit 65: OPKO Health - Geographic focus
Exhibit 66: OPKO Health - Segment focus
Exhibit 67: OPKO Health - Key offerings
Exhibit 68: OPKO Health - Key customers
Exhibit 69: Zogenix - Overview
Exhibit 70: Zogenix - Business segments
Exhibit 71: Zogenix - Organizational developments
Exhibit 72: Zogenix - Geographic focus
Exhibit 73: Zogenix - Segment focus
Exhibit 74: Zogenix - Key offerings
Exhibit 75: Zogenix - Key customers
-

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る